Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | HMG-CoA reductase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | STE/STE11 serine/threonine-protein kinase, putative | 0.0536 | 0.2308 | 1 |
Loa Loa (eye worm) | STE/STE11/ASK protein kinase | 0.0536 | 0.2308 | 0.2312 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0855 | 0.4298 | 0.4298 |
Schistosoma mansoni | P2X receptor subunit | 0.0855 | 0.4298 | 0.4298 |
Schistosoma mansoni | P2X receptor subunit | 0.0855 | 0.4298 | 0.4298 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0855 | 0.4298 | 0.4298 |
Echinococcus granulosus | mitogen activated protein kinase kinase kinase | 0.177 | 1 | 1 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0855 | 0.4298 | 0.4298 |
Mycobacterium ulcerans | hydroxymethylglutaryl-coenzyme a (HMG-CoA) reductase | 0.0165 | 0 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.177 | 1 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0855 | 0.4298 | 0.4298 |
Trypanosoma brucei | 3-hydroxy-3-methylglutaryl-CoA reductase, putative | 0.0165 | 0 | 0.5 |
Leishmania major | 3-hydroxy-3-methylglutaryl-CoA reductase | 0.0165 | 0 | 0.5 |
Schistosoma mansoni | protein kinase | 0.177 | 1 | 1 |
Schistosoma mansoni | protein kinase | 0.177 | 1 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.0855 | 0.4298 | 0.4298 |
Loa Loa (eye worm) | hypothetical protein | 0.0533 | 0.2292 | 0.2295 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0855 | 0.4298 | 0.4298 |
Schistosoma mansoni | P2X receptor subunit | 0.0855 | 0.4298 | 0.4298 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0855 | 0.4298 | 0.4298 |
Loa Loa (eye worm) | hypothetical protein | 0.1767 | 0.9984 | 1 |
Trypanosoma cruzi | STE/STE11 serine/threonine-protein kinase, putative | 0.0536 | 0.2308 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = -6.6 | Ability to inhibit HMG-CoA reductase (HMGR) by CoA reductase inhibition screen (COR) in rats | ChEMBL. | 2296019 |
IC50 (binding) | = -6.4 | Ability to inhibit HMG-CoA reductase (HMGR) by cholesterol synthesis inhibition screen (CSI) in rats | ChEMBL. | 2296019 |
IC50 (binding) | = 0.23 uM | Inhibition of HMG-CoA reductase activity in partially purified rat liver | ChEMBL. | 1992137 |
IC50 (binding) | = 0.23 uM | Ability to inhibit HMG-CoA reductase (HMGR) by CoA reductase inhibition screen (COR) in rats | ChEMBL. | 2296019 |
IC50 (binding) | = 0.23 uM | Inhibition of HMG-CoA reductase activity in partially purified rat liver | ChEMBL. | 1992137 |
IC50 (binding) | = 0.23 uM | Ability to inhibit HMG-CoA reductase (HMGR) by CoA reductase inhibition screen (COR) in rats | ChEMBL. | 2296019 |
IC50 (binding) | = 0.4 uM | Ability to inhibit HMG-CoA reductase (HMGR) by cholesterol synthesis inhibition screen (CSI) in rats | ChEMBL. | 2296019 |
IC50 (binding) | = 0.4 uM | Ability to inhibit HMG-CoA reductase (HMGR) by cholesterol synthesis inhibition screen (CSI) in rats | ChEMBL. | 2296019 |
Log IC50 (binding) | = -6.6 | Ability to inhibit HMG-CoA reductase (HMGR) by CoA reductase inhibition screen (COR) in rats | ChEMBL. | 2296019 |
Log IC50 (binding) | = -6.4 | Ability to inhibit HMG-CoA reductase (HMGR) by cholesterol synthesis inhibition screen (CSI) in rats | ChEMBL. | 2296019 |
Relative potency (functional) | = 10.9 | Relative potency against HMG-CoA reductase activity in partially purified rat liver | ChEMBL. | 1992137 |
Relative potency (functional) | = 10.9 | Relative potency against HMG-CoA reductase activity in partially purified rat liver | ChEMBL. | 1992137 |
Relative potency (binding) | = 30.2 | Ratio of inhibitory activity of compound against HMG-CoA reductase to that of compactin | ChEMBL. | 2296019 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.